Verve Therapeutics Inc (NASDAQ: VERV) Is A Bargain Stock You Should Consider.

In the last trading session, 1.76 million Verve Therapeutics Inc (NASDAQ:VERV) shares changed hands as the company’s beta touched 1.76. With the company’s per share price at $6.45 changed hands at -$0.58 or -8.25% during last session, the market valuation stood at $546.08M. VERV’s last price was a discount, traded about -199.84% off its 52-week high of $19.34. The share price had its 52-week low at $4.30, which suggests the last value was 33.33% up since then.

Analysts gave the Verve Therapeutics Inc (VERV) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.40. If we narrow down to specifics, the data shows that 1 out of 8 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 2 recommended VERV as a Hold, 5 felt it is a Buy and 0 rated the stock as Underweight.

Verve Therapeutics Inc (NASDAQ:VERV) trade information

Instantly VERV was in red as seen at the end of in last trading. With action -23.98%, the performance over the past five days has been red. The company’s shares are showing year-to-date upside of 14.36%, with the 5-day performance at -23.98% in the red. However, in the 30-day time frame, Verve Therapeutics Inc (NASDAQ:VERV) is -18.46% down.

The consensus price target for the stock as assigned by Wall Street analysts is 14, meaning bulls need an upside of 53.93% from its current market value. According to analyst projections, VERV’s forecast low is 14 with 14 as the target high. To hit the forecast high, the stock’s price needs a -117.05% plunge from its current level, while the stock would need to soar -117.05% for it to hit the projected low.

Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -67.06%. The 2025 estimates are for Verve Therapeutics Inc earnings to increase by 22.12%, but the outlook for the next 5-year period is at 2.28% per year.